Targeted therapy in head and neck cancer.

ENT Department, University Hospital of Ferrara, Ferrara, Italy.
Tumori (Impact Factor: 1.09). 97(2):137-41. DOI: 10.1700/667.7773
Source: PubMed

ABSTRACT This review focuses on recent advances in understanding the molecular mechanisms at the basis of cancer initiation and progression in the head and neck and also discusses the possible development of targeted cellular strategies. Intrinsic and acquired resistance of cancer cells to current conventional treatments, as well as recurrence, represent a major challenge in treating and curing the most aggressive and metastatic tumors also in the head and neck. Even though in some hematologic malignancies (i.e., non-Hodgkin's lymphomas) antibodies specifically designed to target tumor-specific cells have already been introduced, in solid tumors molecular targeted therapy is now entering clinical practice.
A PubMed database systematic review.
Molecular targeting could achieve specific damage to cancer cells, at the same time preserving functionally important tissues. This could offer new prospectives in primary and adjuvant treatment also of head and neck tumors.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in JAK-STAT signaling pathway genes have been associated with the development of various hematological tumors, but have not been investigated in head and neck tumors, and the PIK3CA, BRAF and KRAS genes have been described in a few cases of head and neck squamous cell carcinoma (HNSCC). In the present study, we determined the mutation status in members of the MAPK, PI3K-AKT and JAK-STAT pathways in HNSCC. Mutations in the KRAS, BRAF, PIK3CA, JAK1 and JAK2 genes were evaluated in 94 HNSCCs by direct DNA sequencing analysis using cDNA synthesized from RNA extracted from patient tumor cells. All patients evaluated had wild-type KRAS, BRAF and PIK3CA genes. Furthermore, although some known polymorphisms have been found in JAK1 genes (rs45598436, rs17127063, rs2230587, rs3737139, rs2230588 and rs12129819) and JAK2 (rs10429491, rs2230723, rs2230724 and rs41316003), no mutation could be detected. Our data indicate that mutations in these kinase genes seem to be rare events in HNSCC.
    Oncology Reports 05/2013; 30(1). DOI:10.3892/or.2013.2455 · 2.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Um die Prognose von Patienten mit Plattenepithelkarzinomen des Kopf-Hals-Bereichs (PKH) zu verbessern, ist die Weiterentwicklung der Immuntherapie notwendig, bei der tumorspezifische Antigene eine zielgerichtete onkologische Therapie ermöglichen. Gerade Patienten mit PKH verfügen aber über ausgeprägte immunsuppressive Mechanismen und Funktionseinschränkungen wichtiger Effektorzellen. Eine erfolgreiche Immuntherapie könnte durch die Restitution dieser Zellpopulationen eine effektive antitumorale Immunantwort induzieren. Gegenwärtige antitumorale immuntherapeutische Strategien umfassen u. a. die unspezifische Immunstimulation, genetische Modifikationen von Tumor- oder Immunzellen, die Verwendung monoklonaler Antikörper, wie z. B. Cetuximab, die adoptive Immuntherapie wie auch die Impfung. Diese biologischen Therapien könnten in Zukunft entweder allein oder in Kombination mit konventionellen Behandlungskonzepten eine wertvolle Therapieergänzung für Patienten mit PKH darstellen.
    HNO 01/2013; 61(7). DOI:10.1007/s00106-012-2635-6 · 0.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasing information concerning molecular biology of viruses and virus-cell interactions makes possible to use viruses as a tool in effort to treat cancer diseases. As a rule, tumor cells are highly sensitive to viruses that may be used in cancer therapy. Therewith, applications of viral oncolysis in treatment of cancer diseases assume maximum possible safety of used viruses for patient and environment. Human enteroviruses are one of the convenient sources to generate oncolytic viruses. Many of enteroviruses are non-pathogenic for humans or cause mild disease. Progress in genetic engineering permits to develop attenuated enterovirus variants with high safety and selectivity. This review focuses on the main members of Enterovirus genus, such as Coxsackieviruses, and vaccine strains as promising source for development of oncolytic agents, applicable for cancer therapy. It reviews data concerning recently developed and tested oncolytic variants of enteroviruses and discusses perspectives of their application in cancer therapy and problems, concerning their improvement and practical use.
    Molecular Biology 09/2012; 46(5-6):712-725. DOI:10.1134/S0026893312050032 · 0.74 Impact Factor

Full-text (2 Sources)

Available from
May 21, 2014